A Randomized Controlled Trial of ProstAtak as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer

Trial Profile

A Randomized Controlled Trial of ProstAtak as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PrTK03
  • Sponsors Advantagene
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Apr 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
    • 12 Sep 2016 According to an Advantagene media release, this study will be conducted under a Special Protocol Assessment agreement with the U.S. Food & Drug Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top